An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Nuvation Bio Announces Departure of Chief Financial Officer
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Nuvation Bio Inc. (NUVB) announces the resignation of Chief Financial Officer Jennifer Fox to pursue new opportunities. Ms. Fox seeks later stage development and commercial launch experience, leaving with high regard for the Company. Her resignation is effective November 27, 2023. Executive and finance team members will assume CFO duties and responsibilities.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Nuvation Bio Inc. (NYSE: NUVB) (the “Company”) announced today that Jennifer Fox will be stepping down from her role as Chief Financial Officer to pursue a new opportunity. Ms. Fox has advised the Company that she is seeking later stage development and commercial launch experience as part of her career development and that she is leaving with a high regard for the Company, its leadership and its financial state. Ms. Fox submitted her resignation on November 9, 2023 with an effective date of November 27, 2023. Members of the executive management team and the Company’s finance team will assume the duties and responsibilities of the CFO office.
“Jen has played an integral role in helping to set the strategic and financial direction for Nuvation Bio, and I want to thank her for her dedication and hard work in moving Nuvation Bio forward,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “We owe her a great deal of gratitude for her contributions and wish her all the best in her future endeavors.”
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.
Why is Jennifer Fox stepping down from her role as Chief Financial Officer at Nuvation Bio Inc.?
Jennifer Fox is stepping down to pursue a new opportunity seeking later stage development and commercial launch experience.
When is Jennifer Fox's resignation effective?
Jennifer Fox submitted her resignation on November 9, 2023, with an effective date of November 27, 2023.
Who will assume the duties and responsibilities of the CFO office at Nuvation Bio Inc.?
Members of the executive management team and the Company’s finance team will assume the duties and responsibilities of the CFO office.
What did David Hung, Founder, President, and CEO of Nuvation Bio Inc., say about Jennifer Fox's resignation?
David Hung thanked Jennifer Fox for her dedication and hard work in moving Nuvation Bio forward, expressing gratitude for her contributions and wishing her all the best in her future endeavors.
nuvation bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. nuvation bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world’s leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.
